The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
作者： Daniel John Renouf , Petr Kavan , Neesha C Dhani , Derek J Jonker , Alice Chia-chi Wei
DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS4149
关键词: Oncology 、 Internal medicine 、 Gemcitabine 、 Monoclonal antibody 、 Tremelimumab 、 Medicine 、 Pancreatic ductal adenocarcinoma 、 Phases of clinical research 、 Nab-paclitaxel 、 Durvalumab
摘要: TPS4149Background: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) has become a standard 1st line therapy for advanced PDAC based on the MPACT Trial.Durvalumab (D) is human monoclonal antibody (mAb)...
sci-hub.st 参考文章(0)